Risankizumab for Ulcerative Colitis
2024 · JAMA · 98 citations
https://doi.org/10.1001/jama.2024.12414
T
Toshimitsu Fujii
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
176
Papers
2.6K
Citations
26
h-index
54
i10-index
Toshimitsu Fujii is an academic researcher from Tokyo Institute of Psychiatry. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Autoimmune and Inflammatory Disorders. The author has an h-index of 26, co-authored 150 publications.
ORCID: 0000-0003-3048-7270Papers by this author
worksGuselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study
2023 · Gastroenterology · 88 citations
https://doi.org/10.1053/j.gastro.2023.08.038
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies
2024 · The Lancet · 67 citations
https://doi.org/10.1016/s0140-6736(24)01927-5
The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease
2010 · Journal of Gastroenterology · 46 citations
https://doi.org/10.1007/s00535-010-0352-z
Comparative Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis: A Real‐World Multicentre Study in Japan
2024 · Alimentary Pharmacology & Therapeutics · 33 citations
https://doi.org/10.1111/apt.18406
Efficacy and safety of filgotinib for ulcerative colitis: A real‐world multicenter retrospective study in Japan
2024 · Alimentary Pharmacology & Therapeutics · 32 citations
https://doi.org/10.1111/apt.17961
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat